



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# The ER5 splice variant increases oestrogen responsiveness of ERpos Ishikawa cells

### Citation for published version:

Collins, F, Itani, N, Esnal Zufiaurre, A, Gibson, DA, Fitzgerald, C & Saunders, PT 2019, 'The ER5 splice variant increases oestrogen responsiveness of ERpos Ishikawa cells', *Endocrine-Related Cancer*.  
<https://doi.org/10.1530/ERC-19-0291>

### Digital Object Identifier (DOI):

[10.1530/ERC-19-0291](https://doi.org/10.1530/ERC-19-0291)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

Endocrine-Related Cancer

### Publisher Rights Statement:

Open Access - CC-BY

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



ERbeta5 and endometrial cancer

**The ERβ5 splice variant increases oestrogen responsiveness of ERα<sup>pos</sup> Ishikawa cells.**

Frances Collins, Nozomi Itani\*, Arantza Esnal-Zufiaurre, Douglas A Gibson, Carol Fitzgerald\*\* and Philippa TK Saunders

The University of Edinburgh Centre for Inflammation Research, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh Bioquarter, Edinburgh, EH16 4TJ. UK

\*current address: Division of Women's Health, Women's Health Academic Centre, King's College London and King's Health Partners, London, UK

\*\* current address: DePuy Synthes Johnson & Johnson Ireland Ltd  
Unit 2, Block 10, Blanchardstown Corporate Park Dublin 15, Ireland

**Running title:** ERbeta5 and endometrial cancer.

Word count: 5217, Figures: 6, References: 41

Correspondence: Professor Philippa TK Saunders  
Centre for Inflammation Research,  
The University of Edinburgh,  
Queen’s Medical Research Institute,  
47 Little France Crescent,  
Edinburgh Bioquarter  
Edinburgh, EH16 4TJ. UK.  
Email: p.saunders@ed.ac.uk

## ERbeta5 and endometrial cancer

**Abstract**

Endometrial cancer is a common gynaecological malignancy: life time exposure to oestrogen is a key risk factor. Oestrogen action is mediated by receptors encoded by *ESR1* (ER $\alpha$ ) and *ESR2* (ER $\beta$ ): ER $\alpha$  plays a key role in regulating endometrial cell proliferation. A truncated splice variant isoform (ER $\beta$ 5) encoded by *ESR2* is highly expressed in cancers. This study explored whether ER $\beta$ 5 alters oestrogen responsiveness of endometrial epithelial cells.

Immunohistochemistry profiling of human endometrial cancer tissue biopsies identified epithelial cells co-expressing ER $\beta$ 5 and ER $\alpha$  in stage I endometrial adenocarcinomas and post menopausal endometrium. Induced co-expression of ER $\beta$ 5 in ER $\alpha$ <sup>pos</sup> endometrial cancer cells (Ishikawa) significantly increased ligand-dependent activation of an ERE-luciferase reporter stimulated by either E2 or the ER $\alpha$ -selective agonist 1,3,5-(4-Hydroxyphenyl)-4-Propyl-1H-pyrazole (PPT) compared to untransfected cells. Fluorescence recovery after photobleaching (FRAP) analysis of tagged yellow fluorescent protein (YFP)-ER $\beta$ 5 transfected into Ishikawa cells revealed that incubation with E2 induced a transient reduction in intra-nuclear mobility characterised by punctate protein redistribution which phenocopied the behaviour of ER $\alpha$  following ligand activation with E2. In ER $\alpha$ <sup>neg</sup> MDA-MD-231 breast cancer cells there was no E2-dependent change in mobility of YFP-ER $\beta$ 5 and no activation of the ERE reporter in cells expressing ER $\beta$ 5.

In conclusion, we demonstrate that ER $\beta$ 5 can act as heterodimeric partner to ER $\alpha$  in Ishikawa cells and increases their sensitivity to E2. We speculate that expression of ER $\beta$ 5 in endometrial epithelial cells may increase the risk of malignant transformation and suggest that immunostaining for ER $\beta$ 5 should be included in diagnostic assessment of women with early grade cancers.

## ERbeta5 and endometrial cancer

**Introduction**

Endometrial cancer is the most common gynaecological malignancy in the developed world with the majority presenting as abnormal bleeding in post-menopausal women; the incidence of this cancer is increasing in parallel with changing demographics characterized by an aging population and increased prevalence of obesity (Sanderson, et al. 2017). Clinically, endometrial cancers are routinely classified as having a type I or type II phenotype, with the former being oestrogen-dependent and the latter oestrogen-independent (Bokhman 1983).

A study examining the risk factors for type I and type II endometrial cancers based on 14,069 cancer cases, reported that risk of developing either type of malignancy was influenced by parity, oral contraceptive use, age at menarche, and diabetes but higher BMI had a greater effect on the risk of developing a type I tumour (Setiawan, et al. 2013). A genome wide-significant association between endometrial cancer and a *CYP19A1* (aromatase gene) SNP associated with increased circulating E2 concentrations has been reported (Thompson, et al. 2016). In pre-menopausal women the primary source of endogenous oestrogens are the ovaries although local biosynthesis can also occur in the endometrium (Gibson, et al. 2013; Gibson and Saunders 2012). After menopause synthesis of oestrogens in non-ovarian sites such as adipose tissue predominates but expression of oestrogen biosynthetic enzymes including CYP19A1, HSD17B1 and sulfatase within endometrial cancer tissues is consistent with intracrine biosynthesis of bioactive oestrogens from blood borne steroid precursors. For example sulfatase converts of E1-S to E1, and HSD17B1 can convert E1 to E2 (reviewed in (Rizner, et al. 2017; Sinreih, et al. 2017)).

Oestrogenic ligands (endogenous or synthetic) can induce phenotypic changes that can contribute to increased cancer risk including proliferation, angiogenesis, migration and epithelial to mesenchymal transition by binding to oestrogen receptors which act as ligand-activated transcription factors. In women the key nuclear oestrogen receptors are ER $\alpha$ ,

## ERbeta5 and endometrial cancer

71 encoded by *ESR1*, and ER $\beta$  encoded by *ESR2*: both receptors are expressed in endometrial  
72 tissue during the normal menstrual cycle (Critchley, et al. 2002). Studies using knockout mice  
73 have highlighted the importance of *Esr1* in mediating the proliferative effects of oestrogens  
74 on endometrial epithelial cells (Winuthayanon, et al. 2017). A study of ~6000 cancer patients,  
75 reported a strong risk signal for endometrioid cancers was located in a promoter of *ESR1*  
76 (O'Mara, et al. 2015).

77 In common with other members of the nuclear receptor family (van der Vaart and Schaaf  
78 2009), the *ESR1* and *ESR2* genes are subject to alternative splicing with both C terminal and  
79 exon-skipping isoforms identified in cancer cell lines and human tissues including the testis  
80 (Saunders, et al. 2002). In this paper we have focused on a C-terminal splice variant of *ESR2*  
81 called ER $\beta$ 5 which contains an identical sequence encoded by exons 1-7 of the wild type  
82 protein (sometimes called ER $\beta$ 1 to distinguish it from variant isoforms) but incorporates a  
83 unique 8th exon. The resultant protein has an intact DNA binding domain but lacks amino  
84 acids in the E/F domains of ER $\beta$ 1 which contribute to the ligand binding pocket and binding  
85 of co-factors critical for a robust response to ligand (Gibson and Saunders 2012; Poola, et al.  
86 2005). This splice variant does not exist in rodents. We have previously developed a specific  
87 antibody to the unique C-terminus of the protein and confirmed expression in endometrial and  
88 other cancers (Collins, et al. 2009; Shaaban, et al. 2008; Wong, et al. 2005). Despite lacking  
89 an intact ligand binding domain, cell line studies have reported that co-expression of ER $\beta$ 5  
90 can have alter transcriptional activity of ERs in response to oestrogens. For example, in COS7  
91 cells (SV40 transformed monkey kidney cells) ER $\beta$ 5 was able to bind DNA in a gel shift  
92 assay and inhibited the activity of ER $\alpha$ , but not ER $\beta$ 1, on a TGF-beta3-CAT gene reporter  
93 (Peng, et al. 2003; Poola et al. 2005). In HEK293 (embryonic kidney) cells ER $\beta$ 1:ER $\beta$ 5  
94 heterodimers induced greater expression of an ERE reporter gene in response to incubation  
95 with E2 but ER $\alpha$  co-transfection was not tested (Leung, et al. 2006). Overexpression of ER $\beta$ 5

## ERbeta5 and endometrial cancer

in PC3 cells (metastatic, ER $\beta^{\text{pos}}$ , prostate cancer cells) increased cell migration (Leung, et al. 2010). Taken together these results suggest that expression of ER $\beta$ 5 can have an impact on oestrogen-responsiveness and therefore has the potential to alter oestrogen-driven progression of malignancy in cancers, albeit in a cell-context dependent manner.

In support of this, some reports suggest immunoexpression of ER $\beta$ 5 could be a useful prognostic indicator in cancer. Wimberley et al (Wimberly, et al. 2014) reported immunoexpression of ER $\beta$ 5 was associated with worse outcome in triple negative/HER-2 breast cancer patients. In a study on prostate cancer cytoplasmic ER $\beta$ 5 staining was associated with a reduced survival time to post-operative metastases (Leung et al. 2010). Over-expression of ER $\beta$ 5 has also been reported in colon cancers (Wong et al. 2005), glioma (Li, et al. 2013), cancers of the ovary (Ciucci, et al. 2014) and of the thymus (Li, et al. 2015) however to date the impact of ER $\beta$ 5 in endometrial cancers is unknown.

In this study we have demonstrated co-expression with of ER $\beta$ 5 with ER $\alpha$  in epithelial cell nuclei of stage I endometrial adenocarcinomas and provided novel evidence to support formation of ER $\alpha$ :ER $\beta$ 5 heterodimers in cell line model of endometrial adenocarcinoma (Ishikawa). These results suggest the presence of ER $\beta$ 5 in ER $\alpha$  positive cells may augment the oestrogen-sensitivity of cells and drive malignant transformation.

## Materials and Methods

### Patients and tissue collection

Endometrial adenocarcinomas had previously been recovered from post-menopausal women (n=101) undergoing total abdominal hysterectomy. Written informed consent was obtained from all patients and ethical approval granted by the Lothian Research Ethics committee (LRE 1999/6/4) as detailed in (Collins et al. 2009). Additional (control) samples (n=9) were

## ERbeta5 and endometrial cancer

obtained from women who were postmenopausal (14 months to 26 years after their self-reported last menstrual period) and attending clinics for treatment of benign gynaecological conditions, including heavy menstrual bleeding. In all cases women were recruited by dedicated research nurses and written consent was obtained prior to tissue collection under Research ethics 10/S1402/59 or 07/S1103/29. Tissue for immunohistochemistry was fixed in 4% neutral buffered formalin overnight at 4°C. Tissue for RNA extraction was collected in RNALater (Qiagen). All cancers were confined to the uterus (stage I). Grading of tissues as well (G1), moderately (G2) or poorly differentiated (G3), was performed by an expert gynaecological pathologist according to the FIGO (International Federation of Obstetrics and Gynaecology) grading system (Scully, et al. 1994). We have previously used a subset of samples from this tissue archive and conducted DAB immunohistochemistry to investigate immunoexpression of individual *ESR2*-encoded proteins (Collins et al. 2009).

### Cell lines

Endometrial epithelial adenocarcinoma Ishikawa cells were originally derived from a well differentiated adenocarcinoma in a 39 year old pre-menopausal woman (Nishida, et al. 1985): catalogue no 99040201, (ECACC, Wiltshire, UK). RL95-2 endometrial epithelial carcinoma cells derived from a moderately differentiated 64yr old, catalogue no RL95-2 ATCC-CRL-1671 (LGC Standards, Middlesex, UK). MFE-280 endometrial epithelial adenocarcinoma cells derived from a poorly differentiated endometrial carcinoma from a 78yr old, catalogue no ECACC-98050131 (Public Health England, Salisbury, UK) p68, Lot no 11J030. The human MDA-MB-231 breast adenocarcinoma cell line was originally isolated from pleural effusions of a Caucasian 51-year old breast cancer patient (ECACC catalogue no. 92020424). The source and authentication of cell lines are described in Supplementary Table 1 using the ICLAC cell line checklist as a template.

## ERbeta5 and endometrial cancer

Cells were maintained at 37°C, 5% CO<sub>2</sub> in DMEM supplemented with 1% non-essential amino acids, 2mM L-glutamine, 10<sup>5</sup>U/L penicillin, 100mg/L streptomycin, 1.25g/l fungizone and 10% heat inactivated fetal bovine serum (FBS). For experiments, cells were grown for 48h in phenol red free DMEM supplemented with 10% charcoal stripped FBS (CSFBS). Previous studies in our laboratory had established that the MDA-MB-231 cells did not contain either mRNA or protein encoded by *ESR1*, whereas the Ishikawa cells used in this study contained both ERα mRNA and protein (Collins et al. 2009). Comparison of Ishikawa RL95-2 and MFE endometrial cancer cells revealed that endogenous expression of ERα could only be detected in the Ishikawa cells where it was approximately 1:1 with ERβ5 (Supplementary Figure 2): failure to detect ERα in the other cells would be consistent with loss of expression in less differentiated cancer cells (see Collins et al. 2009).

### **Transient transfections to establish cell lines expressing different receptor ratios**

Adenoviral constructs expressing full length ERα, ERβ1 and ERβ5 cDNAs were prepared as described previously (Bombail, et al. 2010). In order to generate proteins with fluorescent protein tags for FRAP analysis (see below) full length cDNAs encoding human ERα and ERβ5 were subcloned between the Eco RI and Bam HI restriction sites in plasmid vectors expressing yellow fluorescent protein (pEYFP-C1) or cyan fluorescent protein expression vector (pECFP-C1) (Clontech (Mountain View, CA, USA). Inserts (YFP/CFP-receptor) were subcloned into the pDC315 shuttle vector (Microbix) recombined into the adenoviral genome (pBHGLOx deltaE1, Cre, Microbix) and used to generate high titre stocks as previously described (Bombail et al. 2010). To generate an Ad-ERE-Luc reporter the cDNA from a plasmid construct containing a 3xERE-tk-luciferase reporter gene that was a kind gift from Professor DP McDonnell (Hall, 1999), Duke University NC, USA) was sub-cloned into an adenoviral vector and particles purified as described above (Bombail et al. 2010).



## ERbeta5 and endometrial cancer

To establish cells with expression of ER $\alpha$ , ER $\beta$ 1 and ER $\beta$ 5 MDA-MD-231 and Ishikawa cells were plated at  $1 \times 10^5$  cells/ml in phenol red free DMEM with 10% CSFCS for 24h prior to infection with adenovirus expressing each receptor at multiplicity of infection (MOI) of 50 for 4h before replacing the media with serum free DMEM. The cells were cultured for 24h for RNA expression and 48h for protein expression. To establish Ishikawa cells with an ER $\beta$ 5 > ER $\alpha$  ratio adenovirus expressing ER $\beta$ 5 was used at a MOI of 75 and ER $\alpha$  was knocked down using a Silencer Select Predesigned siRNA (Ambion/Life). Cells were seeded at  $1 \times 10^5$  cells/ml and grown to 60-70% confluence before being transfected with lipofectamine RNAiMAX (Life) and 15pmol of siRNA per well. Cells were incubated for 48h for mRNA expression and 72h for protein expression. Cells were stimulated with vehicle control (ethanol), E2  $10^{-8}$ M (Sigma) or  $10^{-8}$ M of the ER $\alpha$ -selective agonist PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, Tocris. (Meyers, et al. 2001) for 8h

## RNA extraction and Taqman quantitative RT-PCR

RNA extraction from tissues or cells was performed as described in (Collins et al. 2009): RNA concentration and purity was measured using the Nanodrop (LabTech International, Lewes, UK) and standardised to 100ng/ $\mu$ l for all samples. Reverse transcription was performed using 100ng of RNA with 0.125x Superscript Enzyme in 1x VILO reaction mix (Life, Paisley, UK) at 25°C for 10 min, followed by 42°C for 60 min and finally 85°C for 5 min. Quantitative PCR was performed using probes for genes of interest from the Universal Probe Library (Roche Diagnostics, Burgess Hill, UK) and specific primers as detailed in (Collins et al. 2009).

## Double Fluorescent Immunohistochemistry on tissue sections

Tissue sections were subjected to antigen retrieval in citrate buffer pH6 and processed according to standard laboratory protocols. Sections were first incubated with mouse

## ERbeta5 and endometrial cancer

monoclonal ER $\beta$ 5 (clone 5/25. BioRad, cat no. MCA4676T) diluted 1:200 in normal goat serum (NGS) overnight at 4°C, followed by goat anti-mouse peroxidase fab (Abcam) 1:500 in serum for 30 min at room temperature and finally incubated with Tyramide Fluorescein (PerkinElmer, Cambridgeshire, UK) at 1:50 in kit diluent for 10 min. Antibody elution was carried out by boiling sections in citrate buffer for 2.5 min followed by 30 min rest, incubated in NGS for 30 min at RT, blocked by Streptavidin/biotin following manufacturer's instructions (Vector, Peterborough, UK). Sections were washed and incubated with ER $\alpha$  mouse monoclonal (Vector, Cat no. VP-E614) at 1:80 in NGS overnight at 4°C. Slides were incubated with goat anti-mouse biotinylated (Abcam) at 1:500 in serum for 30 min at RT, followed by Streptavidin Alexa fluor 546 (Molecular Probes, Paisley, UK) 1:200 in PBS for 1h. Sections were washed, counterstained with DAPI (Sigma, Poole, UK) at 1:1000 in PBS for 10 min before finally mounting in Permafluor (PerkinElmer). All washes between antibodies were carried out 3 times in TBS. Full details of antibodies used in the study are provided in Supplementary Table 2.

## Luciferase reporter assays.

The first set of experiments consisted of Ishikawa and MDA-MD-231 cells (either uninfected) or infected with adenovirus containing constructs for ER $\alpha$  or ER $\beta$ 5 alone, or both ER $\alpha$  and ER $\beta$ 5 at MOI of 50. In a second set of experiments Ishikawa cells were stably infected with ER $\beta$ 5 at MOI of 75 (to overexpress ER $\beta$ 5) or transfected with a siRNA specific for ER $\alpha$  (using reagents in siER $\alpha$  assay ID s4824 silencer select, Invitrogen) allowing the functional impact of different ratios of ER $\alpha$  to ER $\beta$ 5 to be examined. In both experiments cells were plated at  $1 \times 10^5$  cells /ml in 24 well tissue culture plates in DMEM with 10% CSFBS and cultured for 24h before infection with Ad-ERE-Luc vector at MOI of 50; media was replenished after 4h. Cells were incubated for 24h prior to treatment with vehicle control (ethanol), E2  $10^{-8}$ M (Sigma, Poole, UK) or PPT  $10^{-8}$ M (Tocris). Luciferase activities were

## ERbeta5 and endometrial cancer

determined using Bright-Glo luciferase reagents according to the manufacturer's instructions (Promega).

### **Fluorescence Recovery after Photobleaching (FRAP).**

Cells cultured on 35mm cover slips in 60mm plates (Mat-Tek) at  $1 \times 10^5$  cells/ml were infected with each of the viral constructs (MOI 50) for 24h prior to live cell imaging. Cells were maintained in 2.5% HEPES/PBS solution on a heated stage at 37°C. Only cells with relatively low levels of fluorescence were used in the FRAP experiment to avoid problems associated with overexpression and the bulk averaging of large numbers of nuclei.

FRAP was conducted using a Zeiss LSM 510 laser scanning confocal microscope. Images were captured in a 256 X by 100 Y frame through 63X objective lens before and after ligand treatment at 3sec intervals for up to 30sec after bleaching. Bleaching was carried out on a single z-section of the chosen cell (ROI I) with excitation of the Argon 12 laser (488 and 514nm) and emission via the 530-600 band pass yellow filter. The pinhole was kept open to the maximum and the number of iterations kept at 100. The fluorescence intensity data was normalised for each cell and used for in a non-linear regression model,  $Y=Y_{\max} \times (1-e^{-Kx})$  (GraphPad Prism 4), where the regression coefficient  $r^2$  was typically 0.95. The  $Y_{\max}$  and half-life of recovery values ( $0.69/K$ ) were averaged for at least 20 cells per treatment.

### **Statistical Analysis of FRAP measurements.**

The bleached area was designated Region of Interest I (ROI I). A second unbleached region in the same cell (ROI II) was used to normalise the bleached area. A third region (ROI III) was chosen outside the nucleus of interest to ensure the bleaching effect was focused on ROI I only. Fluorescence intensity of the bleached region over the time course of scans were normalised against those of ROI II to account for the differences in immunofluorescent levels throughout the cell nucleus. All scanned images post-bleach were normalised against the pre-

## ERbeta5 and endometrial cancer

bleached state to derive the percentage recovery (and to allow for differences in actual strength of bleaching between cells). The first image post-bleach was subsequently normalised to 0 and recovery rates defined against this value. Variability between cells was resolved by normalising time at bleaching to 0 and successive scan times measured against this. A non-linear regression curve fit was carried out on the resultant figures. This generated the values of  $Y_{MAX}$  (maximum level of recovery at which values reach a plateau) and Half-time (time taken in seconds to reach half of the  $Y_{MAX}$ ). Unpaired t-tests of the regression statistics were carried out to compare these between the treated versus ligand stimulated cells. Significant differences were noted as those with  $P \leq 0.05$ .

## Results

*ERβ5 mRNA and protein are expressed in both normal endometrium and endometrial adenocarcinomas*

Messenger RNAs for both ERα and ERβ5 were detected in endometrial samples from post-menopausal women (PMC, 9, Figure 1 A, B). Expression levels of ERα mRNA were significantly lower in cancers graded as G1 well-defined ( $p < 0.01$ ), G2 moderately defined ( $p < 0.01$ ) or G3 poorly defined ( $p < 0.001$ ) than in PMC (Figure 1A). ERβ5 mRNA expression appeared to be higher in the cancers than the PMC tissue although the wide variation between patients meant this did not reach statistical significance (Figure 1B). These findings extend those previously reported on a subset of 30 of these 101 endometrial cancer samples (Collins et al. 2009).

*Immunofluorescent co-staining of ERβ5 and ERα identified epithelial cells which express both proteins in type I endometrial cancers.*

Fluorescent co-staining with antibodies specific for ERα or ERβ5 identified cells expressing one (green, red) or both (yellow/orange) proteins in stage I endometrial cancers (Figure 2). In

## ERbeta5 and endometrial cancer

samples of well- and moderately- differentiated cancers there was a well-defined epithelial layer surrounding gland-like structures (G) which had intense immunostaining for ERβ5 (green nuclei, Figure 2. A-C), but within the stroma there were cells that appeared to express ERα (red) alone (fibroblast-like shape) (Figure 2. A-C). In samples with a more disorganised tissue architecture (Figure 2. D-F) there was no distinct gland structure but coexpression of ERβ5 and ERα was readily detected (yellow/orange cell nuclei). When the green (ERβ5) and red (ERα) channels were separated it was apparent that the intensity of immunostaining for ERα in epithelial cells was variable whereas ERβ5 appeared more uniform resulting in variable ratios of ERα:ERβ5 in individual epithelial nuclei (Figure 3).

In endometrium from postmenopausal women both ERα and ERβ5 proteins were detected with evidence of co-expression in some epithelial cells lining the glands whereas those lining the lumen appeared to lack ERα (Supplementary Figure 1).

### *ERβ5 enhances E2-dependent activation of an ERE reporter gene*

To investigate if ERβ5 expression altered oestrogen responsiveness, two cell lines were used: endometrial Ishikawa cells that contained both ERβ5 and ERα mRNAs (ratio ~1:1) and MDA-MB-231 breast cancer cells which were ERα negative and had only very low levels of endogenous ERβ5 mRNA (Supplementary Figure 3). Like MDA-MB-231 two endometrial cancer cell lines (RL92-2, MFE) that were evaluated also lacked endogenous ERα mRNAs but had much higher concentrations of ERβ5 which made them unsuitable for the transfection study. In addition to these wild-type cell lines transfections of each cell line were undertaken using adenoviral vectors containing ERα (Ad-ERα) or ERβ5 (Ad-ERβ5) alone or in combination. In response to treatment with E2, or the ERα-selective agonist PPT (Meyers et al. 2001), wild-type Ishikawa cells significantly increased expression of a luciferase reporter gene under the control of an ERE response element compared to vehicle (Figure 4A). Transfection with Ad-ERβ5 significantly increased luciferase expression in response to E2

## ERbeta5 and endometrial cancer

(Figure 4A) or PPT (Figure 4B) compared with wild-type cells or those transfected with Ad-ER $\alpha$  (Figure 4B). Co-transfection of cells with Ad-ER $\alpha$ +AdER $\beta$ 5 did not increase expression of luciferase in the Ishikawa cells beyond that of the cells infected with ER $\beta$ 5 alone in response to E2 (Figure 4A) and appeared to blunt the response to PPT (Figure 4B). In line with expectations, MDA-MD-231 cells did not upregulate expression of the ERE-luc reporter in response to E2 or PPT unless they were infected with Ad-ER $\alpha$  either alone or in combination with Ad-ER $\beta$ 5 (Figure 4C, D). In contrast to Ishikawa cells transfection with Ad-ER $\beta$ 5 had no impact on expression of the ERE-luc reporter consistent with MDA-MD-231 cells lacking endogenous ER $\alpha$  (Figure 4 C, D).

To extend these studies ERE reporter activation in Ishikawa cells that expressed three different ratios of mRNAs encoded by the receptors were compared: a) wildtype cells ~1:1 ratio (ER $\alpha$ :ER $\beta$ 5), b) cells infected with Ad-ER $\beta$ 5 (ratio ER $\beta$ 5:ER $\alpha$  ~1.5:1), c) cells depleted of ER $\alpha$  using siRNA-mediated knockdown (ER $\beta$ 5:ER $\alpha$  ~2.5:1). Protein knockdown resulting in reduced expression of ER $\alpha$  were confirmed by Western blot (Supplementary Figure 4). Consistent with earlier findings wild type cells and those with enhanced expression of ER $\beta$ 5 both increased expression of the ERE-luc reporter in response to E2 with a significant increase in the Ad-ER $\beta$ 5 cells compared to wild-type (Figure 5). The importance of ER $\alpha$  was confirmed by siRNA knockdown and by incubation of the cells with the anti-oestrogen ICI (Figure 5).

*FRAP analysis of YFP-ER $\beta$ 5 reveals altered mobility in response to E2 in Ishikawa cells*

As ERE reporter studies suggested that ER $\beta$ 5 could alter transcriptional activity in Ishikawa cells when co-expressed with ER $\alpha$ , further experiments were performed to explore whether this was associated with formation of ER $\alpha$ /ER $\beta$ 5 hetero-dimers.

## ERbeta5 and endometrial cancer

Live cell imaging and FRAP was used to explore the dynamics of YFP-tagged ERβ5 in the nuclei of ERα<sup>pos</sup> Ishikawa and ERα<sup>neg</sup> MDA-MD-231 cells using established methods (Bombail et al. 2010). Following transfection of Ishikawa cells with the majority of YFP-ERβ5 protein being detected in the nuclear compartment in line with expectations FRAP analysis revealed that in cells treated with DMSO (vehicle control) this protein was highly mobile (Figure 6 C, D). Addition of E2 resulted in changes in the appearance of some but not all cell nuclei. In one population of cells where there was no evidence of altered mobility in response to E2 (Figure 6 A, C) but in second population of cells incubation with E2 induced a rapid reduction in intra-nuclear receptor mobility and adoption of a ‘punctate’ distribution (Figure 6 B, D). Further detailed analysis of the latter revealed that the punctate appearance was both rapid and transient, peaking ~20 minutes after introduction of E2 (Figure 6. E, F). Mobility of YFP-ERβ5 in MDA-MD-231 cells was not altered by treatment with E2 even when cells were co-transfected with ERα (Supplementary Figure 5): these results are consistent with the results obtained using the ERE-luciferase reporter.

## Discussion

Life-time exposure to oestrogens, treatment with drugs with oestrogenic activity, exposure to endocrine disruptors, or oestrogen exposure unopposed by progesterone (for example during the peri-menopause) have all been implicated in rising rates of endometrial cancer (reviewed in (Rizner et al. 2017; Sanderson et al. 2017).

In contrast to the limited data on ERβ5 a large number of publications have suggested that ERβ1, the full length *ESR2* isoform which has an intact ligand binding pocket, acts as a negative modulator of ERα in breast and other cancer cells (Chang, et al. 2006)(Zhao, et al. 2007). A systematic review of evidence from immunohistochemical studies of breast cancers concluded that the positive association between ERβ1 expression and 5-year overall survival was only evident in ERα positive patients (Liu, et al. 2016). Structural analyses also suggest

## ERbeta5 and endometrial cancer

338 ER $\alpha$  $\beta$  heterodimers are more stable than ER $\beta$  $\beta$  homodimers and conservation of peptides  
339 implicated in the heterodimeric interaction in ER $\beta$ 5 are consistent with historical gel shift  
340 studies reporting this variant can dimerise (Chakraborty, et al. 2012; Poola et al. 2005). In a  
341 study using single chain ERs to explore the relative contributions of ER $\alpha$  and ER $\beta$ 1 to  
342 heterodimer activities Li et al (Li, et al. 2004) reported ER $\alpha$  is the functionally dominant  
343 partner in ER $\alpha$ /ER $\beta$ 1 heterodimers. The results of the current study appear to be in agreement  
344 with this observation with binding of ligand to ER $\alpha$  essential to the activation of reporter  
345 constructs.

346 Our studies in endometrial cancer tissue are in agreement with other results reporting  
347 expression of ER $\beta$ 5 protein is upregulated in a number of hormone-responsive cancers  
348 compared with equivalent non malignant tissues (Li et al. 2015). Smith et al identified  
349 different exons (E0K, E0N) in the 5'UTR sequences of *ESR2* transcripts (Smith, et al. 2010)  
350 and showed that the translational efficiency of a GFP reporter gene was higher when the  
351 promoter contained the E0N exon sequence. They highlighted the importance of translational  
352 regulation in determining expression levels of *ESR2* variants, including ER $\beta$ 5, in breast  
353 cancer cell lines (Smith et al. 2010). They also speculated that overexpression of eIF4E could  
354 explain an increase in the translational efficiency *ESR2* variants such as ER $\beta$ 5 in cancer.  
355 Although it would be interesting determine which 5'UTR drives expression of ER $\beta$ 5 variant  
356 mRNAs in endometrium and whether this is altered in endometrial cancers this was outside  
357 the scope of the current investigation.

358 In this study we have, for the first time, demonstrated that ER $\alpha$  and ER $\beta$ 5 proteins are co-  
359 expressed in endometrial adenocarcinomas with evidence that most epithelial cells in stage I  
360 cancers were immunopositive for ER $\beta$ 5 but with variable expression of ER $\alpha$ . These results  
361 are in agreement with previous findings obtained using a subset of the current samples and  
362 single colour staining (see figure 2 in (Collins et al. 2009). A paper by Haring and colleagues



## ERbeta5 and endometrial cancer

(Haring, et al. 2012) has reported that the ratio of ERβ5:ERα mRNA rises in parallel with grade.

As ERβ5 protein is clearly expressed in some endometrial cancers in a pattern that overlaps with that of ERα we used a variety of cell-based methods to explore whether this might alter the response of cells to E2. Studies were conducted in Ishikawa cells which expressed endogenous ERα as well as MDA-MD-231 cells which had no native ERα: significant differences in the impact of overexpression of ERβ5 in these cell backgrounds were apparent when their oestrogen-responsiveness was assessed using a reporter gene under the control of an ERE promoter. In the Ishikawa cells overexpression of ERβ5 resulted in a significant *increase* in reporter gene activity in response to either E2 or PPT, an ERα-selective agonist. Further studies using siRNAs confirmed that activation of the reporter gene was ERα-dependent. In contrast in MDA-MD-231 cells there was no induction of the ERE reporter in wild type cells or those transfected with Ad-ERβ5. A key question arising from these studies was how does ERβ5 increase ERα-dependent ERE activation even though the protein is unable to bind E2? One possible explanation is that it stabilises a conformation of ERα that favours co-activator recruitment. In this study we showed that the ratio between the different receptors makes a difference to activation of the ERE reporter in Ishikawa cells with a ratio of ERβ5:ERα mRNAs of between 1:1 and 1.5:1 able to enhance reporter responses. In MDA-MD-231 cells co-expression of ERβ5 with ERα did not enhance response to E2 or PPT above that of ERα alone. It has been reported that ERβ5 can inhibit ERα-dependent activation of an ERE reporter gene in COS7 cells (Peng et al. 2003). Older papers have also reported that greater ratios of ERβ5 (10:1 ERα) resulted in reduced expression of ERα (Poola et al. 2005). These contrasting results suggest cell context (availability of cofactors?) as well as the ratios of ER subtypes can alter oestrogen responsiveness but still need to be repeated in a wider range of cell types to validate this hypothesis

## ERbeta5 and endometrial cancer

388 Reporter gene activation is a useful and widely employed read-out of oestrogen response but  
389 FRAP is a more powerful tool as it allows for monitoring the mobility of receptor proteins in  
390 real time in individual cells. The Mancini group have published a number of elegant studies  
391 documenting intranuclear dynamics of fluorescent-tagged ER $\alpha$  protein (Stenoien, et al. 2000;  
392 Stenoien, et al. 2001a; Stenoien, et al. 2001b). They showed that in the absence of steroid  
393 ligand ER $\alpha$  is highly mobile within the nuclear environment and that addition of E2 results in  
394 reduced mobility which they suggest reflects enhanced interactions with immobile nuclear  
395 proteins (Stenoien et al. 2001b). In the current study we report novel evidence that the intra-  
396 nuclear mobility of YFP-tagged ER $\beta$ 5 was altered in response to E2 in Ishikawa cells. The  
397 time frame of the immobilisation and recovery of the YFP-ER $\beta$ 5 mirrored that of tagged ER $\alpha$   
398 constructs used in our own and other studies including the redistribution into a 'punctate'  
399 pattern. ER $\beta$ 5 lacks amino acids corresponding to Helix 12 in the wild-type ER $\beta$ 1 protein. It  
400 has been reported that these sequences are required for ligand-dependent immobilisation of  
401 ER $\alpha$  (Stenoien et al. 2001b) hence the formation of a heterodimer with ligand-activated ER $\alpha$   
402 is the most likely mechanism by which this change in ER $\beta$ 5 mobility is occurring. Notably, in  
403 the current study, not all Ishikawa cells transfected with YFP-ER $\beta$ 5 showed altered  
404 intranuclear mobility in response to E2. Immunostaining of cells from cultures of Ishikawa  
405 cells used in this study with anti-ER $\alpha$  antibodies (data not shown) revealed variable  
406 expression of ER $\alpha$  leading us to conclude reduced mobility of YFP-ER $\beta$ 5 in E2 treated cells  
407 is restricted to those cells that are ER $\alpha$ <sup>pos</sup>. We also noted parallels between these results and  
408 those of a previous study using Ishikawa cells in which we detected changes in intranuclear  
409 mobility of an FP-tagged construct of an orphan member of the nuclear receptor superfamily  
410 ERR $\beta$  which like ER $\beta$ 5 lacks an intact ligand binding domain (Bombail et al. 2010).

411 We also performed some experiments using MDA-MD-231 breast cancer cells which lacked  
412 endogenous ER $\alpha$ . Notably, whilst a change in nuclear mobility of YFP-ER $\alpha$  was detected in

## ERbeta5 and endometrial cancer

response to E2 co-transfection of YFP-ERβ5 and ERα did not result in altered mobility of the YFP-ERβ5 receptor and we speculate that this cell environment did not favour formation of stable heterodimers (see supplementary Figure 3). These results highlight the importance of using cells with a phenotype that is close to the disease under consideration.

ERβ5 may also have roles in cancer that are independent of ERα. The sequence of the protein contains an intact N terminal domain containing amino acids might be susceptible to phosphorylation by growth factor dependent pathways resulting in steroid ligand-independent activation. This has not been tested but may provide a mechanistic explanation as to why expression of ERβ5 is associated with worse outcomes in HER2-positive and triple-negative patients (Wimberly et al. 2014) and can have an impact on response to chemotherapeutic agent induced apoptosis (Lee, et al. 2013).

Recent efforts to expand our understanding of disease progression have used molecular rather than morphological criteria to define subtypes of endometrial cancers. For example, The Cancer Genome Atlas (TCGA) identified four major endometrial cancer groups (1-4): *POLE* mutations, microsatellite instability, copy-number low/microsatellite stable, and copy-number high/‘serous-like’ (Cancer Genome Atlas Research, et al. 2013). Notably in this analysis the authors identified three robust clusters termed ‘mitotic’, ‘immunoreactive’ and ‘hormonal’ based on their RNA analysis with the hormonal subgroup being comprised of endometrioid grade 1/2 tissues exhibiting upregulation of hormone responsive genes including ESR1 and PR (Cancer Genome Atlas Research et al. 2013). In future studies it would be interesting to see whether upregulated expression of ESR2 (including ERβ5) is also associated with this cluster.

In summary, our results provide novel evidence that expression of ERβ5 may increase oestrogen responsiveness of ERα<sup>pos</sup> in some endometrial cancer cells by forming ERβ5-ERα heterodimers. A limitation of our study is that only one endometrial cancer cell line was used

## ERbeta5 and endometrial cancer

as other lines tested lacked endogenous ER $\alpha$  hence generalisation of the findings to all endometrial cancers requires investigation in other cells as well as integration with the latest genomic datasets. We suggest that expression of ER $\beta$ 5 should be considered in risk assessment of women with early grade endometrial cancer as this may inform therapeutic strategies.

### **Declaration of Interests**

None

### **Funding**

Studies in the corresponding author's laboratory were supported by MRC Programme Grants G1100356/1 and MR/N024524/1. CF was supported by a MRC funded PhD studentship paid for from core training funds allocated to the MRC Reproductive Sciences Unit.

### **Author contributions**

Designed study: PTKS

Performed experiments : FC, NI, AE-Z, CF

Original draft of manuscript : PTKS

Revisions and final draft of manuscript: FC, DAG, PTKS

### **Acknowledgements**

We are grateful to Professor Richard Anderson and his research nurses who undertook collection of the endometrial cancer samples as detailed in Collins et al 2009. Thanks are also due to Dr Pamela Brown of the The Shared University Research Facilities (SuRF) based at the Queen's Medical Research Institute who provided high titre stocks of adenovirus.

## ERbeta5 and endometrial cancer

460

## ERbeta5 and endometrial cancer

## 461 References

- 462 Bokhman JV 1983 Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* **15** 10-  
463 17.
- 464 Bombail V, Collins F, Brown P & Saunders PT 2010 Modulation of ER alpha transcriptional  
465 activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long-  
466 and short-form splice variants. *Mol Cell Endocrinol* **314** 53-61.
- 467 Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y,  
468 Shen H, Robertson AG, Pashtan I, Shen R, et al. 2013 Integrated genomic characterization of  
469 endometrial carcinoma. *Nature* **497** 67-73.
- 470 Chakraborty S, Willett H & Biswas PK 2012 Insight into estrogen receptor beta-beta and  
471 alpha-beta homo- and heterodimerization: A combined molecular dynamics and sequence  
472 analysis study. *Biophys Chem* **170** 42-50.
- 473 Chang EC, Frasor J, Komm B & Katzenellenbogen BS 2006 Impact of estrogen receptor beta  
474 on gene networks regulated by estrogen receptor alpha in breast cancer cells. *Endocrinology*  
475 **147** 4831-4842.
- 476 Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G & Gallo D 2014 Prognostic  
477 significance of the estrogen receptor beta (ERbeta) isoforms ERbeta1, ERbeta2, and ERbeta5  
478 in advanced serous ovarian cancer. *Gynecol Oncol* **132** 351-359.
- 479 Collins F, Macpherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN &  
480 Saunders PT 2009 Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants,  
481 in endometrial cancers and evidence that prostaglandin F may play a role in regulating  
482 expression of ERalpha. *BMC Cancer* **9** 330.
- 483 Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP & Saunders PT  
484 2002 Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both

## ERbeta5 and endometrial cancer

- 485 expressed within the human endometrium throughout the normal menstrual cycle. *J Clin*  
 486 *Endocrinol Metab* **87** 5265-5273.
- 487 Gibson DA, McInnes KJ, Critchley HO & Saunders PT 2013 Endometrial Intracrinology--  
 488 generation of an estrogen-dominated microenvironment in the secretory phase of women. *J*  
 489 *Clin Endocrinol Metab* **98** E1802-1806.
- 490 Gibson DA & Saunders PT 2012 Estrogen dependent signaling in reproductive tissues - A  
 491 role for estrogen receptors and estrogen related receptors. *Mol Cell Endocrinol* **348** 361-372.
- 492 Haring J, Skrzypczak M, Stegerer A, Latrich C, Weber F, Gorse R, Ortmann O & Treeck O  
 493 2012 Estrogen receptor beta transcript variants associate with oncogene expression in  
 494 endometrial cancer. *Int J Mol Med* **29** 1127-1136.
- 495 Lee MT, Ho SM, Tarapore P, Chung I & Leung YK 2013 Estrogen receptor beta isoform 5  
 496 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis  
 497 through interaction with Bcl2L12. *Neoplasia* **15** 1262-1271.
- 498 Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL & Ho SM 2010 Estrogen  
 499 receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote  
 500 cancer cell migration and invasion. *Endocr Relat Cancer* **17** 675-689.
- 501 Leung YK, Mak P, Hassan S & Ho SM 2006 Estrogen receptor (ER)-beta isoforms: a key to  
 502 understanding ER-beta signaling. *Proc Natl Acad Sci U S A* **103** 13162-13167.
- 503 Li SY, Wang YX, Wang L, Qian ZB & Ji ML 2015 Cytoplasm estrogen receptor beta5 as an  
 504 improved prognostic factor in thymoma and thymic carcinoma progression. *Oncol Lett* **10**  
 505 2341-2346.
- 506 Li W, Winters A, Poteet E, Ryou MG, Lin S, Hao S, Wu Z, Yuan F, Hatanpaa KJ, Simpkins  
 507 JW, et al. 2013 Involvement of estrogen receptor beta5 in the progression of glioma. *Brain*  
 508 *Res* **1503** 97-107.

## ERbeta5 and endometrial cancer

- 509 Li X, Huang J, Yi P, Bambara RA, Hilf R & Muyan M 2004 Single-chain estrogen receptors  
510 (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in  
511 genomic estrogen signaling pathways. *Mol Cell Biol* **24** 7681-7694.
- 512 Liu J, Guo H, Mao K, Zhang K, Deng H & Liu Q 2016 Impact of estrogen receptor-beta  
513 expression on breast cancer prognosis: a meta-analysis. *Breast Cancer Res Treat* **156** 149-  
514 162.
- 515 Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS & Katzenellenbogen JA  
516 2001 Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies  
517 of diarylpropionitriles and their acetylene and polar analogues. *J Med Chem* **44** 4230-4251.
- 518 Nishida M, Kasahara K, Kaneko M, Iwasaki H & Hayashi K 1985 [Establishment of a new  
519 human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and  
520 progesterone receptors]. *Nippon Sanka Fujinka Gakkai Zasshi* **37** 1103-1111.
- 521 O'Mara TA, Glubb DM, Painter JN, Cheng T, Dennis J, Australian National Endometrial  
522 Cancer Study G, Attia J, Holliday EG, McEvoy M, Scott RJ, et al. 2015 Comprehensive  
523 genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. *Endocr*  
524 *Relat Cancer* **22** 851-861.
- 525 Peng B, Lu B, Leygue E & Murphy LC 2003 Putative functional characteristics of human  
526 estrogen receptor-beta isoforms. *J Mol Endocrinol* **30** 13-29.
- 527 Poola I, Abraham J, Baldwin K, Saunders A & Bhatnagar R 2005 Estrogen receptors beta4  
528 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary  
529 and functional characterization. *Endocrine* **27** 227-238.
- 530 Rizner TL, Thalhammer T & Ozvegy-Laczka C 2017 The Importance of Steroid Uptake and  
531 Intracrine Action in Endometrial and Ovarian Cancers. *Front Pharmacol* **8** 346.



## ERbeta5 and endometrial cancer

- 532 Sanderson PA, Critchley HO, Williams AR, Arends MJ & Saunders PT 2017 New concepts  
 533 for an old problem: the diagnosis of endometrial hyperplasia. *Hum Reprod Update* **23** 232-  
 534 254.
- 535 Saunders PT, Millar MR, Macpherson S, Irvine DS, Groome NP, Evans LR, Sharpe RM &  
 536 Scobie GA 2002 ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in  
 537 distinct cell populations in the adult human testis. *J Clin Endocrinol Metab* **87** 2706-2715.
- 538 Scully R, Bonfiglio T, Kurman R, Silverberg S & Wilkinson E 1994 *Histological Typing of*  
 539 *Female Genital Tract Tumours*. Berlin: Springer Verlag.
- 540 Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N,  
 541 Weiss NS, Webb PM, et al. 2013 Type I and II endometrial cancers: have they different risk  
 542 factors? *J Clin Oncol* **31** 2607-2618.
- 543 Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson  
 544 JF, Paish EC, Saunders PT, et al. 2008 Nuclear and cytoplasmic expression of ERbeta1,  
 545 ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. *Clin*  
 546 *Cancer Res* **14** 5228-5235.
- 547 Sinreih M, Knific T, Anko M, Hevir N, Vouk K, Jerin A, Frkovic Grazio S & Rizner TL 2017  
 548 The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial  
 549 Cancer. *Front Pharmacol* **8** 368.
- 550 Smith L, Brannan RA, Hanby AM, Shaaban AM, Verghese ET, Peter MB, Pollock S,  
 551 Satheesha S, Szykiewicz M, Speirs V, et al. 2010 Differential regulation of oestrogen  
 552 receptor beta isoforms by 5' untranslated regions in cancer. *J Cell Mol Med* **14** 2172-2184.
- 553 Stenoien DL, Mancini MG, Patel K, Allegretto EA, Smith CL & Mancini MA 2000  
 554 Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. *Mol*  
 555 *Endocrinol* **14** 518-534.

## ERbeta5 and endometrial cancer

- 556 Stenoien DL, Nye AC, Mancini MG, Patel K, Dutertre M, O'Malley BW, Smith CL, Belmont  
 557 AS & Mancini MA 2001a Ligand-mediated assembly and real-time cellular dynamics of  
 558 estrogen receptor alpha-coactivator complexes in living cells. *Mol Cell Biol* **21** 4404-4412.
- 559 Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW & Mancini MA  
 560 2001b FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-  
 561 dependent. *Nat Cell Biol* **3** 15-23.
- 562 Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, Doody D, Dennis J,  
 563 Webb PM, Australian National Endometrial Cancer Study G, et al. 2016 CYP19A1 fine-  
 564 mapping and Mendelian randomization: estradiol is causal for endometrial cancer. *Endocr*  
 565 *Relat Cancer* **23** 77-91.
- 566 van der Vaart M & Schaaf MJ 2009 Naturally occurring C-terminal splice variants of nuclear  
 567 receptors. *Nucl Recept Signal* **7** e007.
- 568 Wimberly H, Han G, Pinnaduwa D, Murphy LC, Yang XR, Andrulis IL, Sherman M,  
 569 Figueroa J & Rimm DL 2014 ERbeta splice variant expression in four large cohorts of human  
 570 breast cancer patient tumors. *Breast Cancer Res Treat* **146** 657-667.
- 571 Winuthayanon W, Lierz SL, Delarosa KC, Sampels SR, Donoghue LJ, Hewitt SC & Korach  
 572 KS 2017 Juxtacrine Activity of Estrogen Receptor alpha in Uterine Stromal Cells is  
 573 Necessary for Estrogen-Induced Epithelial Cell Proliferation. *Sci Rep* **7** 8377.
- 574 Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ & Saunders PT 2005  
 575 ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of  
 576 clinicopathological and molecular correlates. *J Pathol* **207** 53-60.

577

578

## ERbeta5 and endometrial cancer

**Figure Legends**

Figure 1. Detection of mRNAs for ER $\alpha$  and ER $\beta$ 5 in endometrial cancers.

Expression of ER $\alpha$ /ER $\beta$ 5 mRNA is altered in women with endometrial cancer compared to post menopausal controls (PMCs). Expression of ER $\alpha$  mRNA (A) and ER $\beta$ 5 mRNA (B) in PMCs (n=9), G1 well differentiated (n=19), G2 moderately differentiated (n=52) and G3 poorly differentiated (n=30). Total RNA for ER $\alpha$  in G1, G2, and G3 (p<0.0001) were significantly lower than PMCs. Expression of ER $\beta$ 5 mRNA appeared to increase in G3 compared to PMC but did not reach significance. Results are expressed as fold difference compared to PMCs with statistical analysis performed by one way anova with Tukey's *post hoc* test, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001.

Figure 2. Co-localisation of ER $\alpha$  and ER $\beta$ 5 in stage 1 endometrial adenocarcinomas identifies variable co-expression of both proteins in a subset of epithelial cells.

Examples of staining in endometrial cancer tissues classified by a pathologist as G1 well (A, B), G2 moderately (C, D) or G3 poorly (E, F) differentiated. Note glands (G) surrounded by a single layer of epithelial cells could be identified in well and some moderately differentiated tissue associated with a stromal compartment (S) containing fibroblasts (s). The architecture of the poorly differentiated cancers less organised and dominated by epithelial cells. Intense immunostaining for ER $\beta$ 5 (green, asterisks) as well as evidence of co-expression of ER $\alpha$  (yellow-red, arrows) was detected in epithelial cells.

Figure 3. Confocal imaging identified epithelial cells in endometrial cancers with variable amounts of ER $\alpha$  and ER $\beta$ 5 proteins.

## ERbeta5 and endometrial cancer

Confocal images typical of endometrial cancers classified as well or moderately differentiated are illustrated showing merged (top panel) and individual channels for ER $\beta$ 5 (green, middle) and ER $\alpha$  (lower red). The intensity of immunostaining for ER $\beta$ 5 appeared similar between different nuclei within each of these samples whereas the amount of protein in nuclei stained with an antibody specific for ER $\alpha$  (red) revealed a range of intensities from low to high with the latter identified by yellow/orange staining in the merged image (examples \* and arrowhead). Scale bars 50 $\mu$ m.

Figure 4. Impact of ER $\beta$ 5 on expression of an ERE-luciferase reporter gene in Ishikawa and MDA-MD-231 cells.

Over expression of ER $\beta$ 5 significantly increased the ERE-luciferase activity in response to E2 (\*\*\*)  $p < 0.001$ ) and PPT (\* $p < 0.05$ ) in Ishikawa cells (A, B). Increased expression of the reporter response to E2 (C) or PPT (D) was detected in MDA-MD-231 cells transfected with ER $\alpha$  (\*\*\*\*  $p < 0.0001$ ) but not with ER $\beta$ 5 alone. The number of replicates ranged from a minimum of 4 on triplicate wells and statistical analysis was performed by one way anova with Tukey's *post hoc* test, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$

Figure 5. ER $\alpha$  plays a critical role in E2-dependent reporter gene activity in Ishikawa cells expressing ER $\beta$ 5.

Overexpression of ER $\beta$ 5 in ER $\alpha^{\text{pos}}$  Ishikawa cells (ratio mRNAs ER $\beta$ 5: ER $\alpha$  = 1.5:1) resulted in a significant increase in reporter gene compared to cells treated with vehicle (24h +/-E2). Targeted knockdown of ER $\alpha$  abrogated response to E2. Results are displayed as fold difference compared to vehicle: triplicate experiments performed in triplicate wells. Statistical

## ERbeta5 and endometrial cancer

analysis performed by one way anova with Tukey's *post hoc* test, \* $p < 0.05$ , \*\* $p < 0.01$ ,  
\*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

Figure 6. FRAP analysis of YFP-tagged ER $\beta$ 5 in Ishikawa identifies a population of cells with altered nuclear mobility of ER $\beta$ 5 in response to E2.

Following incubation of ER $\alpha^{pos}$ , YFP-ER $\beta$ 5 Ishikawa cells with E2 two populations of cells were identified: A) cells in which YFP-tagged ER $\beta$ 5 was uniformly distributed within the nucleus apart from the nucleolus (dark circles) and B) cells in which YFP protein was not uniform but appeared to be concentrated in selected regions (hereafter referred to as 'punctate'). Using the software of the confocal it was possible to determine the mobility of YFP protein within a bleached region of interest (ROI): protein in A cells remained highly mobile regardless of the presence of ligand whereas in B cells addition of E2 resulted in a rapid reduction in mobility. Further analysis of the population of cells exhibiting altered mobility (E, F) revealed that the change in mobility following addition of E2 was time-dependent with the highest percentage of punctate cells at 30 minutes (F). A minimum of 9 to a maximum of 16 individual cells were examined.




Figure 1. Detection of mRNAs for ERα and ERβ5 in endometrial cancers. Expression of ERα/ERβ5 mRNA is altered in women with endometrial cancer compared to post menopaual controls (PMCs). Expression of ERα mRNA (A) and ERβ5 mRNA (B) in PMCs (n=9), G1 well differentiated (n=19), G2 moderately differentiated (n=52) and G3 poorly differentiated (n=30). Total RNA for ERα in G1, G2, and G3 ( $p<0.0001$ ) were significantly lower than PMCs. Expression of ERβ5 mRNA appeared to increase in G3 compared to PMC but did not reach significance. Results are expressed as fold difference compared to PMCs with statistical analysis performed by one way anova with Tukey's post hoc test, \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ , \*\*\*\* $p<0.0001$ .

193x94mm (300 x 300 DPI)




Figure 2. Co-localisation of ER $\alpha$  and ER $\beta$ 5 in stage 1 endometrial adenocarcinomas identifies variable co-expression of both proteins in a subset of epithelial cells. Examples of staining in endometrial cancer tissues classified by a pathologist as G1 well (A, B), G2 moderately (C, D) or G3 poorly (E, F) differentiated. Note glands (G) surrounded by a single layer of epithelial cells could be identified in well and some moderately differentiated tissue associated with a stromal compartment (S) containing fibroblasts (s). The architecture of the poorly differentiated cancers less organised and dominated by epithelial cells. Intense immunostaining for ER $\beta$ 5 (green, asterisks) as well as evidence of co-expression of ER $\alpha$  (yellow-red, arrows) was detected in epithelial cells.




Figure 3. Confocal imaging identified epithelial cells in endometrial cancers with variable amounts of ER $\alpha$  and ER $\beta$ 5 proteins. Confocal images typical of endometrial cancers classified as well or moderately differentiated are illustrated showing merged (top panel) and individual channels for ER $\beta$ 5 (green, middle) and ER $\alpha$  (lower red). The intensity of immunostaining for ER $\beta$ 5 appeared similar between different nuclei within each of these samples whereas the amount of protein in nuclei stained with an antibody specific for ER $\alpha$  (red) revealed a range of intensities from low to high with the latter identified by yellow/orange staining in the merged image (examples \* and arrowhead). Scale bars 50 $\mu$ m.






Figure 4. Impact of ER $\beta$ 5 on expression of an ERE-luciferase reporter gene in Ishikawa and MDA-MD-231 cells. Over expression of ER $\beta$ 5 significantly increased the ERE-luciferase activity in response to E2 (\*\*\*)  $p < 0.001$  and PPT (\* $p < 0.05$ ) in Ishikawa cells (A, B). Increased expression of the reporter response to E2 (C) or PPT (D) was detected in MDA-MD-231 cells transfected with ER $\alpha$  (\*\*\*\*  $p < 0.0001$ ) but not with ER $\beta$ 5 alone. The number of replicates is depicted on each graph and statistical analysis was performed by one way anova with Tukey's post hoc test, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$

208x201mm (300 x 300 DPI)




Figure 5. ERα plays a critical role in E2-dependent reporter gene activity in Ishikawa cells expressing ERβ5. Overexpression of ERβ5 in ERαpos Ishikawa cells (ratio mRNAs ERβ5: ERα = 1.5:1) resulted in a significant increase in reporter gene compared to cells treated with vehicle (24h +/-E2). Targeted knockdown of ERα abrogated response to E2. Results are displayed as fold difference compared to vehicle: triplicate experiments performed in triplicate wells. Statistical analysis performed by one way anova with Tukey's post hoc test, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001.

166x75mm (300 x 300 DPI)




Figure 6. FRAP analysis of YFP-tagged ERβ5 in Ishikawa identifies a population of cells with altered nuclear mobility of ERβ5 in response to E2. Following incubation of ERαpos, YFP-ERβ5 Ishikawa cells with E2 two populations of cells were identified: A) cells in which YFP-tagged ERβ5 was uniformly distributed within the nucleus apart from the nucleolus (dark circles) and B) cells in which YFP protein was not uniform but appeared to be concentrated in selected regions (hereafter referred to as 'punctate'). Using the software of the confocal it was possible to determine the mobility of YFP protein within a bleached region of interest (ROI): protein in A cells remained highly mobile regardless of the presence of ligand whereas in B cells addition of E2 resulted in a rapid reduction in mobility. Further analysis of the population of cells exhibiting altered mobility (E, F) revealed that the change in mobility following addition of E2 was time-dependent with the highest percentage of punctate cells at 30 minutes (F). A minimum of 9 to a maximum of 16 individual cells were examined

## Cell Line Checklist for Manuscripts and Grant Applications

This checklist is a resource for scientists who write or review manuscripts and/or for grant applications that use cell lines. Cross-contaminated cell lines could give unreliable results if used for research because they no longer correspond to the reported donor tissue and so may not represent the correct species, tissue type or disease state. Such misidentified or false cell lines produce unreliable research data and we urge reviewers to highlight their use wherever possible.

This checklist will help the author or reviewer to look for obvious cell line quality concerns. The checklist may also be used to communicate any quality concerns to be addressed prior to publication or funding.

### Manuscript or Grant Information

<i>Title or Manuscript/Grant ID:</i>	ERb5 increases oestrogen responsiveness of Era positive endometrial cancer cells
<i>Cell Lines used:</i>	Ishikawa: Human endometrial adenocarcinoma, ECACC 99040201 MDA-MB-231 Human breast adenocarcinoma ECACC 92020424 RL95: Human endometrial epithelial cancer ATCC CRL-1671 MFE-280: Human endometrial epithelial adenocarcinoma ECACC 98050131
<i>Cell Lines used with Quality Concerns:</i>	

### Cell Line Information

Reporting Requirement	Indicate "Yes" or "No" (No includes Not Known) Add further comment if required
<b>Cell line is known to be cross-contaminated or otherwise misidentified:</b> See the <a href="#">ICLAC website</a> for a register of known misidentified cell lines and Recommendation 1) below.	NO
<b>Authentication testing has been performed:</b> The method and results should be listed. See Recommendation 2) below.	Authentication of Ishikawa and MDA-MB-231 was performed by STR analysis (see attached method and results) RL95 and MFE-280 authenticated by Eurofins (Ebersberg, Germany) using PCR-single-locus-technology
<b>Human cell lines: STR profile is available with the manuscript/grant application:</b>	DNA Profile: Ishikawa  CSF1PO: 11,12 D13S317: 9,12



	Negative control		163	17	0.104	Negative
<b>Source for cell line is listed:</b> The catalogue number should be included if obtained from a cell line repository. See Recommendation 3) below.	Ishikawa: Human endometrial adenocarcinoma, ECACC 99040201 MDA-MB-231 Human breast adenocarcinoma ECACC 92020424 RL95: Human endometrial epithelial cancer ATCC CRL-1671 MFE-280: Human endometrial epithelial adenocarcinoma ECACC 98050131					
<b>RRID Number for cell line is listed:</b> The Resource Identification Initiative (RRID) is meant to help researchers cite the important resources used in scientific papers. See Recommendation 4) below.	Ishikawa (RRID:CVCL_2529) MDA-MB-231 (RRID:CVCL_0062) MFE-280 (RRID:CVCL_1405) RL95-2 (RRID:CVCL_0505)					
<b>Sufficient information is given to replicate experiments using the cell line:</b> See Recommendation 5) below.	Ishikawa passage 16 MDA-MB-231 passage 35 MFE-280 P68 RL95-2 P57 Cells passaged a maximum of 10 times					

## Recommendations

- 1) ICLAC recommends that false cell lines (misidentified cell lines with no known authentic stock) should not be used. ICLAC's register of misidentified cell lines can be found at <http://iclac.org/databases/cross-contaminations>.
- 2) ICLAC recommends that authentication testing should always be performed on established cell lines regardless of the application; the test method and results should be included in the Materials and Methods section. Testing should be done, at minimum, at the beginning and end of experimental work.  
 For human cell lines, short tandem repeat (STR) profiling should be performed and compared to results from donor tissue, or to online databases of human cell line STR reference profiles. More information can be found in the published Standard: ANSI/ATCC ASN-0002-2011 Authentication of Human Cell Lines: Standardization of STR Profiling. [ANSI eStandard Store](#).  
 For non-human cell lines, best practice will vary with the species being tested. At minimum, species should be confirmed using an appropriate method such as karyotyping, isoenzyme analysis, or mitochondrial DNA typing (DNA barcoding).  
 More information on authentication testing can be found at <http://iclac.org/references/>.
- 3) It will be helpful for the reader if authors can include a reference, to provide more information on the cell line's establishment and characterization. However, not all cell lines have this

information available in the public domain.

- 4) Cell line RRIDs are assigned through a collaboration between Cellosaurus and the Resource Identification Initiative. RRIDs can be found by searching for cell lines at <https://web.expasy.org/cellosaurus/>
- 5) This information may include the growth medium used, including additives; any additional growth requirements, including special substrates and gas mixtures; and the passage number or population doubling level (PDL) used for experimental work.  
Passage number is important when working with early passage or finite cultures, or cell lines where changes in phenotype have been documented with increasing passage. ICLAC recommends that laboratories freeze down stocks when they first receive a cell line and set a limit (e.g. 20 passages) to avoid overpassaging. More information can be found at <http://iclac.org/resources/advice-scientists/>

#### **Notes or Further Comments**

Information on Antibodies

Antibody Name	Supplier/Cat number	Target	Species raised, monoclonal/polyclonal	Positive controls	Dilution used following titre optimisation	Comparison with mRNA levels
ER $\alpha$	Vector/VP-E614  Clone:ER6F11  Lot number N/A	Recombinant protein of the full length alpha form of the human estrogen receptor molecule.	Mouse monoclonal	Proliferative endometrium	1:80	✓
ER $\beta$ 5	BioRad/MCA4676T  Clone: 5/25  Lot number:080110	Tuberculin conjugated synthetic peptide LLSHVRHARYAP derived from the C-terminus of human ERB5	Mouse Monoclonal	Colorectal cancer	1:200	✓



### Supplementary Figure legends

Supplementary Figure 1. Immunoexpression of ER $\beta$ 5 and ER $\alpha$  in postmenopausal endometrium.

Immunostaining identified glandular epithelial cells in postmenopausal endometrium that co-expressed ER $\beta$ 5 and ER $\alpha$  in (orange/yellow, asterisks) associated with the glands (G). Notably epithelial cells lining the lumen appeared to be predominantly immunopositive for ER $\beta$ 5 (green). Cells within the stroma were a mixture of immunonegative (blue), ER $\beta$ 5 positive and ER $\beta$ 5/ER $\alpha$  double positive.


Supplementary Figure 2. Expression of ER $\alpha$  and ER $\beta$ 5 mRNAs in endometrial cancer cell lines. Expression of ER $\alpha$  (A) and ER $\beta$ 5 (B) mRNAs in Ishikawa, RL95 and MFE cells. N= 3 per sample with triplicate. Note endogenous ER $\alpha$  mRNAs were only detectable in Ishikawa cells.


Supplementary Figure 3. Comparison between Ishikawa and MDA-MB-231 cells. Note MDA-MB-231 do not contain quantifiable ER $\alpha$ . N=8-10 per sample with triplicate wells.


Supplementary Figure 4. Protein expression in Ishikawa cells in which ratios of ER $\alpha$  and ER $\beta$ 5 were manipulated using a pool of siRNAs directed against ER $\alpha$  or lentivirus containing ER $\beta$ 5. Results were generated by quantification on Western blots using STAT1 as a loading control. N=3 for each condition.


Supplementary Figure 5. FRAP analysis of YFP-tagged ERs in MDA breast cancer cells

Individual MDA-MB-231 cells infected with adenovirus expressing full length YFP-tagged ER $\alpha$  (A, positive control); (B) YFP-ER $\beta$ 5 (C) YFP-ER $\beta$ 5 plus and untagged ER $\alpha$ ; Cells were treated with vehicle alone (DMSO) or vehicle containing E2 10<sup>-8</sup>M. Note analysis of % Recovery of fluorescence after bleaching the ROI identified a significant decrease in nuclear mobility of YFP only in cells infected with ER $\alpha$ -YFP whereas ER $\beta$ 5-YFP remained highly mobile even when exogenous ER $\alpha$  was introduced into the cells suggesting the cellular context of these cells did not support/sustain hetero-dimerisation.











189x93mm (300 x 300 DPI)


A




B




C



D



E



F

